Show simple item record

Entrectinib in patients with ROS1 fusion-positive (ROS1-fp) NSCLC: updated efficacy and safety analysis

dc.contributor.authorFan, Y.
dc.contributor.authorDrilon, A.
dc.contributor.authorChiu, C. H.
dc.contributor.authorBowles, D. W.
dc.contributor.authorLoong, H. H. F.
dc.contributor.authorSiena, S.
dc.contributor.authorGoto, K.
dc.contributor.authorKrzakowski, M.
dc.contributor.authorAhn, M. J.
dc.contributor.authorMurakami, H.
dc.contributor.authorDziadziuszko, R.
dc.contributor.authorZeuner, H.
dc.contributor.authorPitcher, B.
dc.contributor.authorCheick, D.
dc.contributor.authorKrebs, Matthew G
dc.date.accessioned2022-11-30T10:21:20Z
dc.date.available2022-11-30T10:21:20Z
dc.date.issued2022en
dc.identifier.citationFan Y, Drilon A, Chiu CH, Bowles DW, Loong HHF, Siena S, et al. Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis. Journal of Thoracic Oncology. 2022 Sep;17(9):S89-S90. PubMed PMID: WOS:000858678100139.en
dc.identifier.doi10.1016/j.jtho.2022.07.150en
dc.identifier.urihttp://hdl.handle.net/10541/625778
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.jtho.2022.07.150en
dc.titleEntrectinib in patients with ROS1 fusion-positive (ROS1-fp) NSCLC: updated efficacy and safety analysisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentZhejiang Cancer Hospital, Hangzhouen
dc.identifier.journalJournal of Thoracic Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record